New York, NY – Pfizer announced on Tuesday that their vaccine has shown promising results in protecting high-risk adults aged 18 to 59 from respiratory syncytial virus (RSV). The vaccine, known as Abrysvo, has been found to be effective for this age group, potentially offering a wider population protection against RSV. Previously approved for adults 60 and older, as well as expectant mothers, Abrysvo now holds potential for younger, high-risk adults who are vulnerable to severe illness from RSV.
According to Pfizer, RSV causes thousands of hospitalizations and deaths among older Americans each year, as well as hundreds among infants. The virus can also lead to severe illness in younger adults with weakened immune systems or chronic conditions like asthma and diabetes. Pfizer estimates that nearly 10% of U.S. adults aged 18 to 49 have conditions putting them at risk for severe RSV disease, a number that rises to around 24% for those aged 50 to 64.
Dr. Iona Munjal, executive director of clinical vaccine research and development at Pfizer, emphasized the importance of vaccination in protecting high-risk populations against RSV. She highlighted the significance of addressing this issue not only in older populations but also in younger adults with underlying health conditions. Pfizer aims to expand the approval of Abrysvo to include ages 18 and up after submitting the data to regulatory agencies.
In an effort to gain a larger share of the RSV market, Pfizer looks to compete with GlaxoSmithKline (GSK), whose RSV vaccine for adults 60 and above saw significant sales last year. Pfizer recorded approximately $890 million in revenue in 2023 from their shot, while GSK’s vaccine brought in around $1.5 billion. The competition between the two pharmaceutical giants showcases the growing importance of RSV vaccination for different age groups.
Pfizer’s phase three trial results demonstrated the efficacy and safety of their vaccine in high-risk adults aged 50 to 59. By eliciting an immune response against both major subtypes of RSV, the vaccine has shown promise in providing protection similar to that observed in older adults. The company plans to present final trial results at a scientific conference and publish them in a peer-reviewed journal.
Overall, Pfizer’s breakthrough in developing a vaccine for younger, high-risk adults offers hope in combating RSV-related illnesses. The expansion of the Abrysvo vaccine to a broader age range signifies a step forward in protecting vulnerable populations from the debilitating effects of respiratory syncytial virus.